Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 12:19:57 2024-06-03 pm EDT 		5-day change 1st Jan Change
17.45 EUR -6.93% Intraday chart for Frazier Lifesciences Acquisition Corporation -0.37% +67.86%
May. 21 NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings CI
May. 16 Transcript : NewAmsterdam Pharma Company N.V. - Special Call

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 - 830.7 833.1 1,556 - -
Enterprise Value (EV) 1 - 392.2 833.1 1,556 1,556 1,556
P/E ratio -3.39 x -10.6 x -5.1 x -7.42 x -11.5 x -11.9 x
Yield - - - - - -
Capitalization / Revenue - 8.52 x 64.1 x 181 x 247 x 99.4 x
EV / Revenue - 8.52 x 64.1 x 181 x 247 x 99.4 x
EV / EBITDA - - - - - -
EV / FCF - 104 x -6.39 x -8.81 x -12.4 x -10.9 x
FCF Yield - 0.96% -15.6% -11.3% -8.08% -9.21%
Price to Book - 1.71 x - - - -
Nbr of stocks (in thousands) - 81,560 82,324 89,986 - -
Reference price 2 8.575 10.19 10.12 17.29 17.29 17.29
Announcement Date 8/4/22 3/31/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 97.5 13.01 8.608 6.296 15.65
EBITDA - - - - - -
EBIT 1 - -6.96 -168.9 -187.1 -158.2 -160.5
Operating Margin - -7.14% -1,298.56% -2,173.73% -2,513.28% -1,025.19%
Earnings before Tax (EBT) 1 - -78.05 -163.3 -207 -135.9 -141.2
Net income 1 -28.6 -78.05 -163.3 -209.2 -138.7 -139.8
Net margin - -80.05% -1,255.76% -2,430.77% -2,202.72% -893.03%
EPS 2 -2.530 -0.9600 -1.984 -2.330 -1.497 -1.453
Free Cash Flow 1 - 7.959 -130.4 -176.6 -125.7 -143.3
FCF margin - 8.16% -1,002.43% -2,051.13% -1,996.63% -915.26%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/4/22 3/31/23 2/28/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S2 2023 S1 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4 9.562 1.304 1.106 1.83 4.547 - -
EBITDA - - - - - - - -
EBIT 1 - - -51.63 -50.48 -45.73 -39.53 -41.86 -37.26
Operating Margin - - -3,960.17% -4,566.35% -2,499.05% -869.37% - -
Earnings before Tax (EBT) 1 - - -93.77 -47.5 -41.93 -37.16 -38.47 -33.85
Net income 1 - -75.1 -93.77 -48.18 -42.2 -37.62 -38.47 -33.85
Net margin - -785.42% -7,192.76% -4,358.24% -2,306.17% -827.43% - -
EPS 2 - -0.9200 -0.9863 -0.5379 -0.4666 -0.4137 -0.4240 -0.3687
Dividend per Share - - - - - - - -
Announcement Date 3/31/23 8/7/23 5/8/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - 439 - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - 7.96 -130 -177 -126 -143
ROE (net income / shareholders' equity) - -29.2% - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - 5.940 - - - -
Cash Flow per Share - 0.1000 - - - -
Capex 1 - 0.01 0.02 0.92 1.85 2.77
Capex / Sales - 0.01% 0.17% 10.73% 29.37% 17.71%
Announcement Date 8/4/22 3/31/23 2/28/24 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Frazier Lifesciences Acquisition Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
17.29 EUR
Average target price
32.12 EUR
Spread / Average Target
+85.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FRAZIER LIFESCIENCES ACQUISITION CORPORATION Stock Frazier Lifesciences Acquisition Corporation
+67.86% 1.69B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+14.89% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.15% 106B
BIONTECH SE Stock BioNTech SE
-2.96% 24.28B
ARGENX SE Stock argenx SE
+1.14% 21.96B
GENMAB A/S Stock Genmab A/S
-9.35% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.28% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-16.93% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.66% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.34% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. Financials Frazier Lifesciences Acquisition Corporation